Glenmark Pharmaceuticals Limited (Glenmark) has launched the novel fixed-dose combination (FDC) drug-Indacaterol + Mometasone for patients suffering from uncontrolled asthma in India. The firm has launched this FDC under the brand name Indamet.
The drug will increase the accessibility of quality drugs for effective asthma management. The drug will be available in three strengths, with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg, to be taken once daily.
, CDSCO.jpg)
